miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review
Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580823001693 |
| _version_ | 1797317159290929152 |
|---|---|
| author | Thanh Hoa Vo Esam EL-Sherbieny Abdelaal Emmet Jordan Orla O'Donovan Edel A. McNeela Jai Prakash Mehta Sweta Rani |
| author_facet | Thanh Hoa Vo Esam EL-Sherbieny Abdelaal Emmet Jordan Orla O'Donovan Edel A. McNeela Jai Prakash Mehta Sweta Rani |
| author_sort | Thanh Hoa Vo |
| collection | DOAJ |
| description | Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rather aggressive. Although the treatment outcome of HER2+ breast cancer patients has been significantly improved with anti-HER2 agents, primary and acquired drug resistance present substantial clinical issues, limiting the benefits of HER2-targeted treatment. MicroRNAs (miRNAs) play a central role in regulating acquired drug resistance. miRNA are single-stranded, non-coding RNAs of around 20–25 nucleotides, known for essential roles in regulating gene expression at the post-transcriptional level. Increasing evidence has demonstrated that miRNA-mediated alteration of gene expression is associated with tumorigenesis, metastasis, and tumor response to treatment. Comprehensive knowledge of miRNAs as potential markers of drug response can help provide valuable guidance for treatment prognosis and personalized medicine for breast cancer patients. |
| first_indexed | 2024-03-08T03:30:51Z |
| format | Article |
| id | doaj.art-f9e0922ebe34466f9119b0ac537bd412 |
| institution | Directory Open Access Journal |
| issn | 2405-5808 |
| language | English |
| last_indexed | 2024-03-08T03:30:51Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biochemistry and Biophysics Reports |
| spelling | doaj.art-f9e0922ebe34466f9119b0ac537bd4122024-02-11T05:11:10ZengElsevierBiochemistry and Biophysics Reports2405-58082024-03-0137101588miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic reviewThanh Hoa Vo0Esam EL-Sherbieny Abdelaal1Emmet Jordan2Orla O'Donovan3Edel A. McNeela4Jai Prakash Mehta5Sweta Rani6Department of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland; Pharmaceutical and Molecular Biotechnology Research Center, South East Technological University, Cork Road, X91 K0EK, Waterford, IrelandDepartment of Oncology, UPMC Whitfield Hospital, Cork Road, X91 DH9W, Waterford, IrelandDepartment of Oncology, University Hospital Waterford, Dunmore Road, X91 ER8E, Waterford, IrelandDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland; Pharmaceutical and Molecular Biotechnology Research Center, South East Technological University, Cork Road, X91 K0EK, Waterford, IrelandDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland; Pharmaceutical and Molecular Biotechnology Research Center, South East Technological University, Cork Road, X91 K0EK, Waterford, IrelandDepartment of Applied Science, South East Technological University, Kilkenny Road, R93 V960, Carlow, IrelandDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland; Pharmaceutical and Molecular Biotechnology Research Center, South East Technological University, Cork Road, X91 K0EK, Waterford, Ireland; Corresponding author. Pharmaceutical and Molecular Biotechnology Research Center, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland.Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rather aggressive. Although the treatment outcome of HER2+ breast cancer patients has been significantly improved with anti-HER2 agents, primary and acquired drug resistance present substantial clinical issues, limiting the benefits of HER2-targeted treatment. MicroRNAs (miRNAs) play a central role in regulating acquired drug resistance. miRNA are single-stranded, non-coding RNAs of around 20–25 nucleotides, known for essential roles in regulating gene expression at the post-transcriptional level. Increasing evidence has demonstrated that miRNA-mediated alteration of gene expression is associated with tumorigenesis, metastasis, and tumor response to treatment. Comprehensive knowledge of miRNAs as potential markers of drug response can help provide valuable guidance for treatment prognosis and personalized medicine for breast cancer patients.http://www.sciencedirect.com/science/article/pii/S2405580823001693HER2-Positive breast cancermiRNAsTreatment responseHER2 target therapyDrug resistanceDrug sensitivity |
| spellingShingle | Thanh Hoa Vo Esam EL-Sherbieny Abdelaal Emmet Jordan Orla O'Donovan Edel A. McNeela Jai Prakash Mehta Sweta Rani miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review Biochemistry and Biophysics Reports HER2-Positive breast cancer miRNAs Treatment response HER2 target therapy Drug resistance Drug sensitivity |
| title | miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review |
| title_full | miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review |
| title_fullStr | miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review |
| title_full_unstemmed | miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review |
| title_short | miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review |
| title_sort | mirnas as biomarkers of therapeutic response to her2 targeted treatment in breast cancer a systematic review |
| topic | HER2-Positive breast cancer miRNAs Treatment response HER2 target therapy Drug resistance Drug sensitivity |
| url | http://www.sciencedirect.com/science/article/pii/S2405580823001693 |
| work_keys_str_mv | AT thanhhoavo mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT esamelsherbienyabdelaal mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT emmetjordan mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT orlaodonovan mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT edelamcneela mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT jaiprakashmehta mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview AT swetarani mirnasasbiomarkersoftherapeuticresponsetoher2targetedtreatmentinbreastcancerasystematicreview |